373 related articles for article (PubMed ID: 36388082)
1. Biological Mechanisms and Related Natural Inhibitors of CD36 in Nonalcoholic Fatty Liver.
Feng Y; Sun W; Sun F; Yin G; Liang P; Chen S; Liu X; Jiang T; Zhang F
Drug Des Devel Ther; 2022; 16():3829-3845. PubMed ID: 36388082
[TBL] [Abstract][Full Text] [Related]
2. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ
Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823
[TBL] [Abstract][Full Text] [Related]
3. Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Rada P; González-Rodríguez Á; García-Monzón C; Valverde ÁM
Cell Death Dis; 2020 Sep; 11(9):802. PubMed ID: 32978374
[TBL] [Abstract][Full Text] [Related]
4. Prolactin improves hepatic steatosis via CD36 pathway.
Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y
J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209
[TBL] [Abstract][Full Text] [Related]
5. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
6. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
7. The hedgehog pathway in nonalcoholic fatty liver disease.
Verdelho Machado M; Diehl AM
Crit Rev Biochem Mol Biol; 2018 Jun; 53(3):264-278. PubMed ID: 29557675
[TBL] [Abstract][Full Text] [Related]
8. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease.
Teng T; Qiu S; Zhao Y; Zhao S; Sun D; Hou L; Li Y; Zhou K; Yu X; Yang C; Li Y
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887189
[TBL] [Abstract][Full Text] [Related]
10. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
11. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
Zhao L; Zhang C; Luo X; Wang P; Zhou W; Zhong S; Xie Y; Jiang Y; Yang P; Tang R; Pan Q; Hall AR; Luong TV; Fan J; Varghese Z; Moorhead JF; Pinzani M; Chen Y; Ruan XZ
J Hepatol; 2018 Sep; 69(3):705-717. PubMed ID: 29705240
[TBL] [Abstract][Full Text] [Related]
12. B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36.
Zhang H; Li Y; Zhang C; Huang K; Zhao J; Le S; Jiang L; Liu H; Yang P; Xiao X; Yu J; Wu J; Ye P; Xia J
Cell Death Dis; 2022 Apr; 13(4):359. PubMed ID: 35436984
[TBL] [Abstract][Full Text] [Related]
13. Decreased PEDF Promotes Hepatic Fatty Acid Uptake and Lipid Droplet Formation in the Pathogenesis of NAFLD.
Huang KT; Chen KD; Hsu LW; Kung CP; Li SR; Chen CC; Chiu KW; Goto S; Chen CL
Nutrients; 2020 Jan; 12(1):. PubMed ID: 31968655
[TBL] [Abstract][Full Text] [Related]
14. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
15. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
16. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
17. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
[TBL] [Abstract][Full Text] [Related]
18. Transcription factor SOX2 contributes to nonalcoholic fatty liver disease development by regulating the expression of the fatty acid transporter CD36.
Shen C; Chen JH; Oh HR; Park JH
FEBS Lett; 2021 Oct; 595(19):2493-2503. PubMed ID: 34536973
[TBL] [Abstract][Full Text] [Related]
19. Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease.
Pan J; Zhou W; Xu R; Xing L; Ji G; Dang Y
Biomed Pharmacother; 2022 Jul; 151():113127. PubMed ID: 35598367
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
Pydyn N; Miękus K; Jura J; Kotlinowski J
Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]